Yes, pernicious anemia is an autoimmune disease. The immune system produces antibodies that attack the stomach lining and a protein called intrinsic factor, which your body needs to absorb vitamin B12 from food. Without adequate B12, red blood cell production falters and the nervous system can sustain damage over time. It is one of the most common autoimmune blood disorders, though it often takes years to diagnose: survey data from over 1,100 patients found that 40% waited two years or longer before receiving a correct diagnosis.
How the Immune System Causes It
Your stomach contains specialized cells called parietal cells, which sit in the upper portion of the stomach (the corpus and fundus). These cells produce two things: hydrochloric acid for digestion and intrinsic factor, a protein that binds to vitamin B12 so it can be absorbed in the small intestine. In pernicious anemia, the immune system generates two types of antibodies that interfere with this process.
Antiparietal cell antibodies directly destroy the parietal cells themselves, eliminating the source of both acid and intrinsic factor. These antibodies are found in roughly 90% of people with pernicious anemia. Anti-intrinsic factor antibodies, present in about 80% of patients, work differently. Type 1 “blocking” antibodies prevent B12 from attaching to intrinsic factor in the first place. Type 2 “binding” antibodies latch onto the B12-intrinsic factor complex after it forms, stopping the small intestine from absorbing it. The result is the same either way: B12 cannot get from your gut into your bloodstream, no matter how much you consume through food.
This autoimmune destruction of the stomach lining is called autoimmune gastritis, and pernicious anemia develops in about 15 to 20% of people who have it. The damage is slow and progressive, which is part of why diagnosis is so delayed.
Genetic Risk Factors
A large genome-wide study of over 2,100 cases identified five genetic regions that increase susceptibility. Several of these overlap with genes already known to raise risk for other autoimmune conditions. One variant, in the PTPN22 gene, increased risk by about 63% and is a well-known genetic risk factor across multiple autoimmune diseases. Another signal sits in the HLA region on chromosome 6, a stretch of DNA central to immune function. The specific combination of HLA variants linked to pernicious anemia (called the HLA-DR15 haplotype) is also a known risk factor for multiple sclerosis. A variant in the AIRE gene, which helps regulate the immune system’s ability to distinguish the body’s own tissues from foreign invaders, was also significantly associated with the disease.
These findings confirm that pernicious anemia shares a genetic architecture with other autoimmune conditions, which helps explain why it so frequently co-occurs with them.
Conditions That Often Accompany It
People with pernicious anemia are significantly more likely to have other autoimmune diseases. In one study of 74 patients, autoimmune thyroid disease was the most common companion: 60.8% had Hashimoto’s thyroiditis and 16.2% had Graves’ disease. Other co-occurring conditions included vitiligo (12.2%), autoimmune diabetes (31.1%), Sjögren’s syndrome (9.5%), Addison’s disease (6.8%), and antiphospholipid syndrome (6.8%). If you’ve been diagnosed with one autoimmune condition, particularly thyroid disease, it’s worth being aware that B12 deficiency from pernicious anemia could develop alongside it.
Symptoms Beyond Anemia
The name “pernicious anemia” is somewhat misleading because anemia, the shortage of healthy red blood cells, is actually present in only 15 to 20% of people at the time of diagnosis. Many people experience neurological symptoms first, driven by B12’s essential role in maintaining the protective coating around nerves.
Early symptoms typically include tingling and numbness in the hands and feet, fatigue, and weakness. As the deficiency progresses, it can cause difficulty walking, poor balance, stiff or clumsy movements, and falls. Cognitive effects range from mild memory problems and irritability to confusion, depression, and in rare cases, severe dementia or psychosis. A condition called subacute combined degeneration can develop, in which the spinal cord itself deteriorates. Vision problems and persistent sleepiness are also possible. Some of this nerve damage can become permanent if B12 deficiency goes untreated long enough, which makes the long diagnostic delays especially concerning.
How It’s Diagnosed
Diagnosis usually starts with a blood test for serum B12 levels. Values below 200 to 250 pg/mL are generally considered subnormal, though the exact cutoff varies by lab. When levels fall in a gray zone between 150 and 399 pg/mL, a more sensitive marker called methylmalonic acid (MMA) can confirm the deficiency. MMA levels above 0.271 micromol/L suggest B12 deficiency.
Confirming that the deficiency is specifically caused by pernicious anemia (rather than dietary insufficiency or another absorption problem) involves testing for the autoantibodies. Anti-intrinsic factor antibodies are highly specific, meaning a positive result strongly points to pernicious anemia, but they have low sensitivity: fewer than 50% of patients test positive. This means a negative antibody test does not rule the disease out. Antiparietal cell antibodies are detected more often (about 90% of patients) but are less specific, since they also appear in other forms of gastritis. Diagnosis often requires clinical judgment that weighs blood levels, antibody results, symptoms, and response to B12 treatment together.
Treatment and What to Expect
Because pernicious anemia blocks B12 absorption in the gut, oral supplements alone are usually insufficient. The standard treatment is B12 injections. A typical schedule starts with weekly injections for four weeks to replenish depleted stores, followed by monthly injections for life. The injections are given into muscle or just under the skin and use a dose of 1,000 micrograms each time.
For many patients, the standard monthly schedule doesn’t fully control symptoms. Survey data shows that about 50% of patients feel they need more frequent injections to manage their symptoms effectively, while 65% receive injections on the guideline-recommended schedule of every two to three months. Dissatisfaction with injection frequency and a perceived lack of clinician knowledge about the condition led 80% of patients who chose to self-inject to cite improved quality of life as their primary reason. This gap between standard protocols and patient experience is an active area of concern in the pernicious anemia community.
Long-Term Stomach Cancer Risk
Because the autoimmune process destroys the stomach lining over time, pernicious anemia is considered a premalignant condition by both the British Society of Gastroenterology and the American Society for Gastrointestinal Endoscopy. A large study using U.S. Medicare data found that people with pernicious anemia had roughly double the risk of a common type of stomach cancer (non-cardia gastric adenocarcinoma) compared to matched controls. The more striking finding was an 11-fold increase in risk of gastric carcinoid tumors, a type of slow-growing neuroendocrine tumor that arises in the stomach lining. This elevated risk was highest in cases diagnosed six or more years after the initial pernicious anemia diagnosis.
Guidelines differ on surveillance. The American Society for Gastrointestinal Endoscopy recommends a single endoscopy at the time of diagnosis, noting that cancer risk appears greatest within the first year. The British Society of Gastroenterology takes a broader view and considers ongoing endoscopic monitoring justified. European guidelines currently provide no specific screening recommendations. In practice, whether you receive periodic endoscopy depends on your gastroenterologist’s assessment of your individual risk factors.